Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -160.53% is 26% below its 5-year average of -127.43%, near the low end of its 5-year range (-215.74%–-29.49%).
7.86% below its 12-month average of -148.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -26.37%.
RETURN ON ASSETS (ROA)
-160.53%
RETURN ON ASSETS (ROA) AVG TTM
-148.83%
RETURN ON ASSETS (ROA) AVG 3Y
-175.96%
RETURN ON ASSETS (ROA) AVG 5Y
-127.43%
RETURN ON ASSETS (ROA) AVG 10Y
-110.64%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.86%
CURRENT VS 3Y AVG
+8.77%
CURRENT VS 5Y AVG
-25.97%
CURRENT VS 10Y AVG
-45.09%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.09%
median of 848 covered companies
CURRENT VS SECTOR MEDIAN
-400.25%
vs the sector median at left
Decoy Therapeutics Inc.
Market Cap
$843169.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$834497.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$857145.00
Return on Assets (ROA)
-17.34%
TTM Avg
-18.34%
3Y Avg
-35.92%
5Y Avg
-162.42%
Market Cap
$827005.00
Return on Assets (ROA)
N/A
TTM Avg
7.00%
3Y Avg
-3.42%
5Y Avg
-4.05%
Market Cap
$859749.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$862370.00
Return on Assets (ROA)
N/A
TTM Avg
-16.55%
3Y Avg
-16.64%
5Y Avg
-15.27%
Market Cap
$892803.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$669763.00
Return on Assets (ROA)
2.60%
TTM Avg
-212.84%
3Y Avg
-24543.27%
5Y Avg
-19977.79%
Market Cap
$1.03M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | $843169.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $834497.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $857145.00 | -17.34% | -18.34% | -35.92% | -162.42% |
| Ridgetech, Inc. (RDGT)vs › | $827005.00 | N/A | 7.00% | -3.42% | -4.05% |
| Bone Biologics Corporation (BBLG)vs › | $859749.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $862370.00 | N/A | -16.55% | -16.64% | -15.27% |
| GlucoTrack, Inc. (GCTK)vs › | $892803.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| CDT Equity Inc. (CDT)vs › | $669763.00 | 2.60% | -212.84% | -24543.27% | -19977.79% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | -44.32% | -57.72% | -286.30% | -215.47% |
ROA
-160.5%
ROE
-334.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -113.22% |
| 2024-12-31 | -184.45% |
| 2023-12-31 | -190.43% |
| 2022-12-31 | -215.74% |
| 2021-12-31 | -31.27% |
| 2020-12-31 | -29.49% |
| 2019-12-31 | -49.92% |
| 2018-12-31 | -211.00% |
| 2017-12-31 | -98.40% |
| 2016-12-31 | -62.47% |
| 2015-12-31 | -30.65% |
| 2014-12-31 | -22.50% |
